Novozymes Biopharma Aligns Recombinant Human Albumin Portfolio With New Brand Name
The newly announced changes are purely to the brand and visual identity of Novozymes rAlbumins. Customers can be reassured that the products themselves, as well as the product codes, will remain exactly the same. As part of the rebrand customers will see the changes reflected on both marketing materials and product labeling.
The molecule in Novozymes’ two rAlbumin products is identical in respect of amino acid sequence and protein structure. They are both expressed in Novozymes’ proprietary Saccharomyces host and are manufactured in compliance with ICH Q7 cGMP guidelines. The products’ physicochemical properties and customer applications are essentially identical and the name change has been introduced to allow Novozymes to market these two albumins under a single family name.
Novozymes’ rAlbumins provide a secure supply of batch-to-batch consistent materials and are supported by a strongly documented safety package and drug master file. With excellent purity profiles and offering an established pathway through the regulatory approval process, the products have earned a strong reputation in the industry for helping customers to facilitate the safe and successful commercialization of new products.
“Novozymes is delighted to announce that it is synchronizing the branding of its rAlbumin products under the Recombumin family name to enhance the clarity of the company’s product offering, while still providing customers with the same superior solutions”, says Dermot Pearson, Marketing Director, Novozymes Biopharma. He continues, “Since we launched our rAlbumins the portfolio has gone from strength- to-strength helping Novozymes to become one of the fastest growing companies in the industry.”
Novozymes’ rAlbumins are compliant with the National Formulary (NF) rAlbumin human monograph published by the United States Pharmacopeia (USP) and have been optimized to deliver stable, safe and regulatory compliant ingredients for the medical device, drug delivery and formulation markets. Manufactured without animal-derived materials the products can be used in a wide-range of applications including stabilization of drugs and vaccines, device coating, advanced cell therapy products, and in sealants and hemostats.
For further information on Novozymes’ Recombumin Alpha and Recombumin Prime products, please visit www.biopharma.novozymes.com
About Novozymes
Novozymes is the world leader in bioinnovation. Together with customers across a broad array of industries, we create tomorrow’s industrial biosolutions, improving our customers' business and the use of our planet's resources.
With over 700 products used in 130 countries, Novozymes’ bioinnovations improve industrial performance and safeguard the world’s resources by offering superior and sustainable solutions for tomorrow’s ever-changing marketplace. Read more at www.novozymes.com.
Contact:
Novozymes Biopharma:
Niklas Andersson, Global Communications Manager
NLAN@novozymes.com
Tel. +44 115 955 3355
MEDIA CONTACTS
Europe
René Tronborg
Office: +45 4446 2274
Mobile: +45 3077 2274
retr@novozymes.com
China
Zhu Xiaoqing
Office: +86 106 298
7888+362
Mobile: +86 138 012 40590
xqzh@novozymes.com
US
Paige Donnelly
Office: +1 919 494 3209
Mobile: +1 919 218 4501
pagd@novozymes.com
Brazil
Ana Cecilia Amarante de
Oliveira
Office: +55 41 3641 1096
Mobile: +55 41 9619 7594
aaov@novozymes.com
INVESTOR CONTACTS
US
Thomas Steenbech Bomhoff
Mobile: +1 919 649 2565
tsbm@novozymes.com